TriSalus Life Sciences (TLSI) Stock Forecast: StockMap's 2-Week Call
TLSI stock forecast: StockMap's model leans Underperform on TriSalus Life Sciences for the two weeks after the Nov 19 close, toward TLSI trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 4 of 5 two-week windows on TLSI since Aug 21; by chance, a call on the same dates was right 56% of the time.
TriSalus Life Sciences last closed at $2.17, -11.43% on the session.
Against the IVW growth benchmark the position is -9.10% over the forecast window.
TriSalus Life Sciences' market cap is $133.88M as of November 19, 2026.
Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -30 (too close to call).
Where TLSI sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 1 bullish and 14 bearish.
Agreement across those insights is 93%.
29 daily calls for TLSI so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks TriSalus Life Sciences in the 98th percentile on return on equity, where 100 is best.
TriSalus Life Sciences is classified under Health Care / Biotechnology.
StockMap tracks TriSalus Life Sciences as the 258th largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.
On that composite TriSalus Life Sciences ranks 245th of 394 in the group, against a group median of -0.27.